Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
December 12, 2018 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting
December 03, 2018 12:30 ET
|
Helsinn Healthcare S.A.
Phase 2 Interim Data Evaluating the Combination of Pracinostat and Azacitidine in Patients with Myelodysplastic Syndrome Presented at the 2018 American Society of Hematology Annual Meeting LUGANO,...
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
November 27, 2018 10:52 ET
|
Helsinn Healthcare S.A.
The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients LUGANO, SWITZERLAND, AND NEW YORK, NY,...
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018
November 06, 2018 03:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group strengthens the Board with the appointment of Francesco Granata
October 01, 2018 05:05 ET
|
Helsinn Healthcare S.A.
Helsinn Group strengthens the Board with the appointment of Francesco Granata LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting
September 26, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group supports Satellite Symposium at EORTC CLTF 2018 Annual Meeting Lugano, Switzerland, September 26, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care...
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea
July 31, 2018 04:00 ET
|
Helsinn Healthcare S.A.
Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...
Helsinn: Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV)
July 10, 2018 04:11 ET
|
Helsinn Healthcare S.A.
Glenmark Pharmaceuticals expands its oncology franchise in India with the launch of Helsinn’s AKYNZEO®, a combination drug for the prevention of chemotherapy-induced nausea and vomiting (CINV) ...
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S.
June 28, 2018 08:30 ET
|
Helsinn Healthcare S.A.
Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Iselin, NJ, USA, June 28, 2018 – Helsinn Therapeutics (U.S.) Inc., the U.S. subsidiary of...
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid
June 26, 2018 11:59 ET
|
Helsinn Healthcare S.A.
The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid Lugano, Switzerland, June 26, 2018 – The United...